The IndiGo stock has underperformed following a significant miss in the company’s 2Q results, driven by higher costs impacting profitability. However, Jefferies expects cost normalization in the future, viewing the factors behind the higher costs in 2Q as temporary. The brokerage anticipates a return to more typical cost levels, which could improve the company’s performance moving forward.
Q4 results this week: ITC, Sun Pharma, IndusInd Bank, IndiGo, BEL among 81 companies set to announce earnings
India Inc’s Q4 earnings season intensifies with 81 firms, including ITC, Sun Pharma, ONGC, and Hindalco, set to report this week, offering insights into sectoral